Home > News

News

Page 1 of 3  > >>

08 Aug, 2008
Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx® BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
Category: 2008
Posted by: innocoll_admin
ASHBURN, Va., August 8, 2008 /PRNewswire/ -- -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the first of three ongoing phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx® BUPIVACAINE SURGICAL IMPLANT for the management of post-operative pain.
[More]
28 Jul, 2008
Innocoll Announces Dosing of First Patient in a Third US Phase 2 Clinical Trial to Investigate CollaRx® BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
Category: 2008
Posted by: innocoll_admin

ASHBURN, Va., July 28, 2008 /PRNewswire/ -- -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the third of a series of planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx® BUPIVACAINE SURGICAL IMPLANT for the management of post-operative pain, has commenced dosing.

[More]
21 Jul, 2008
Innocoll Appoints Anthony H. Wild Ph.d. to Its Board of Directors
Category: 2008
Posted by: impact99
ASHBURN, Va., July 21, 2008 /PRNewswire/ –– –Innocoll Inc. today announced that Anthony H. Wild, Ph.D. has been appointed to its board of directors.
[More]